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Abstract
Background: Several genome-wide association studies have discovered novel loci at chromosome 12q24, which
includes mevalonate kinase (MVK), methylmalonic aciduria (cobalamin deficiency) cbIB type (MMAB), and potassium
channel tetramerization domain-containing 10 (KCTD10), all of which influence HDL-cholesterol concentrations.
However, there are few reports on the associations between these polymorphisms and HDL-C concentrations in
Chinese population. This study aimed to evaluate the associations between functional polymorphisms in three
genes (MVK, MMAB and KCTD10) and HDL-C concentrations, as well as coronary heart disease (CHD) susceptibility
in Chinese individuals.
Methods: We systematically selected and genotyped 18 potentially functional polymorphisms in MVK, MMAB and
KCTD10 by using the TaqMan OpenArray Genotyping System in a Chinese population including 399 dyslipidemia
cases, 697 CHD cases and 465 controls. Multivariate logistic regression analyses were performed to estimate the
relationship between the genotypes and dyslipidemia, CHD risk with adjustment of relevant confounders.
Results: Among six polymorphisms showing significant associations with dyslipidemia, the minor alleles of rs11066782
in KCTD10, rs11613718 in KCTD10 and rs11067233 in MMAB were significantly associated with a decreased risk of CHD
(additive model: OR = 0.71, 95 % CI = 0.53–0.97, P = 0.029 for rs11066782; OR = 0.73, 95 % CI = 0.54–0.99, P = 0.044
for rs11613718 and OR = 0.57, 95 % CI = 0.40–0.80, P = 0.001 for rs11067233). Further combined analysis showed
that individuals carrying “3-4” favorable alleles presented a 62 % (OR = 0.38, 95 % CI = 0.21–0.66) decreased risk of
CHD compared with those carrying “0–2” favorable alleles.
Conclusions: These findings suggest that rs11066782 in KCTD10, rs11613718 in KCTD10 and rs11067233 in MMAB
may contribute to the susceptibility of CHD by altering plasma HDL-C levels in Han Chinese.
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Background
Coronary heart disease (CHD) is one of the leading causes
of morbidity and mortality in the world [1]. In China, it is
reported that more than 700,000 people die from CHD
each year [2]. CHD is a complex and multifactorial dis-
order caused by various environmental and genetic factors
[3, 4]. Clinical and epidemiological studies have demon-
strated that the presence of low levels of high-density
lipoprotein-cholesterol (HDL-C) in plasma increases the
risk of developing CHD [5–8]. The mechanism by which
HDL-C confers protection against atherosclerosis includes
reverse cholesterol transport from peripheral tissues to the
liver [9], inhibition of low-density lipoprotein-cholesterol
(LDL-C) oxidation, and stabilization of the production
of prostacyclin [10]. While smoking, diet and physical
activity have a role in determining plasma HDL-C con-
centrations, family and twin studies have shown that
about half of the variation in this trait is genetically de-
termined [11, 12]. In 2008, a genome-wide association
study (GWAS) conducted in populations of European
descent discovered novel loci at chromosome 12q24,
which includes mevalonate kinase (MVK), methylmalonic
aciduria (cobalamin deficiency) cbIB type (MMAB), and
potassium channel tetramerization domain-containing 10
(KCTD10), all of which influence HDL-C concentrations
[13]. This association has been consistently replicated in
the subsequent studies [14–16]. MVK encodes the meva-
lonate kinase, which catalyzes an early step in the biosyn-
thesis of cholesterol [17]. MMAB encodes the enzyme
which catalyzes the formation of adenosylcobalamin, a
critical factor for degradation of cholesterol [17]. KCTD10,
which is close to MVK and MMAB genes, has shown
to contribute to the susceptibility of obesity, diabetes
and atherosclerosis [18]. Therefore, MVK, MMAB and
KCTD10 genes may be candidates as susceptibility genes
modulating HDL-C concentrations and then affect the
risk of dyslipidemia and CHD.
To determine whether polymorphisms in MVK, MMAB
and KCTD10 are independently associated with the risk of
dyslipidemia and CHD, we conducted a case–control
study with 399 dyslipidemia cases and 465 controls in
Han Chinese. In addition, for those loci showing signifi-
cant associations with dyslipidemia, we further evaluated
the associations between these polymorphisms and CHD
risk including 697 CHD cases and 465 controls.
Methods
Study population
In this study, we performed a two-stage case–control
study. The first-stage analysis was designed to discover
the suggestive variants associated with dyslipidemia in
a Chinese population consisting of 399 cases and 465
controls from a community based cohort study of non-
infectious diseases in Changzhou and Nantong cities,
Jiangsu Province, China. In this study, eligible subjects
aged over 30 years old were enrolled in 2004 and 2007,
and the baseline information including demographic,
disease history and risk factors for chronic disease was
obtained and a detailed clinical examination was con-
ducted. Physical examinations, including measurements
of height, weight and blood pressure as well as laboratory
tests to measure total cholesterol (TC), triglycerides (TG),
HDL-C and fasting plasma glucose concentrations, were
performed for each subject. Fasting blood samples for rou-
tine laboratory examinations were obtained early in the
morning after an overnight fast. All biochemical parame-
ters were measured enzymatically on an auto-analyzer
(Hitachi 7180 Biochemistry Auto-analyzer, Japan) accord-
ing to the manufacturer’s instructions.
According to the Guidelines on Prevention and Treat-
ment of dyslipidemia in Chinese Adults [19], 399 sub-
jects with HDL-C <1.04 mmol/L were defined as cases
with dyslipidemia (Low-HDL cholesterolemia), while 465
subjects not meeting this criteria were randomly selected
and matched with the cases for age and sex. Subjects
were excluded from the study if they had a history of
diabetes, coronary heart disease or cancer, or those who
were taking lipid-lowering medications.
The second-stage analysis was to determine whether
the loci that influence the HDL-C levels in the first-stage
also have an effect on CHD susceptibility, which consisted
of 697 CHD cases from People's Hospital of Yixing City,
Jiangsu Province, China and 465 controls defined in the
first-stage. In brief, CHD cases were defined as having
angiographic coronary stenosis with ≥50 % lumen reduc-
tion in at least one major epicardial coronary artery. All
patients were genetically unrelated ethnic Han Chinese
from Yixing city. After informed consent was obtained,
the information of demographic characteristics, risk factors
for CHD, history of vascular events and clinical diagnosis
were written from the clinical records. A 5-ml venous
blood sample was collected from each patient.
SNP selection
Based on the public HapMap SNP database (phase II + III
Feb 09, on NCBI B36 assembly, dbSNP b126) and the
HaploView 4.2 software, common SNPs (MAF ≥0.05)
in the three genes (MVK, MMAB and KCTD10) were
screened in gene regions (including 2-kb up-stream re-
gion of each gene) in Chinese Han population. A total
of 21 potentially functional SNPs were selected after the
prediction by using SNPinfo Web Server (http://snpinfo.
niehs.nih.gov/) which is a comprehensive web-based tool
designed to select SNPs based on GWAS results, linkage
disequilibrium, and predict potential functional character-
istics of polymorphisms. Besides, in order to validate the
findings of GWAS [13, 15], rs2338104 and rs7134594
were also included. However, three SNPs were excluded
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for the failed probe design and two SNPs were removed
due to genotyping failure (call rates <95 %). As a result,
18 loci were finally included in the current study. The
linkage disequilibrium (LD) association for the 18 loci
was further analyzed (Additional file 1: Figure S1).
Genotyping
Genomic DNA was isolated from leucocytes of venous
blood by proteinase K digestion and phenol/chloroform
extraction. All SNPs were genotyped by using the TaqMan
OpenArray Genotyping System (Applied Biosystems
lnc, USA). Fluorescence-based polymerase chain reac-
tion (PCR) reagents were used to provide qualitative
detection of targets using post-PCR (endpoint) analysis.
A total volume of 5 μl with 2.5 μl TaqMan OpenArray
Master Mix and 2.5 μl normalized human DNA sample
(50 ng/μl) were loaded and amplified on customized
arrays following the manufacturer’s instructions. Each
48-sample array chip contained two NTCs (no template
controls). All 18 SNPs were successfully genotyped with
call rates >95 %. Additionally, 10 % of samples were
randomly selected for genotyping in duplicates and the re-
sults demonstrated a high degree of concordance (>99 %)
among the duplicate pairs.
Statistical analysis
Data were shown as mean ± standard deviation (SD) or
n (%). Differences in the distributions of demographic
characteristics, selected variables and genotypes frequen-
cies between cases and controls were analyzed by χ2 test
or Student t test. Hardy-Weinberg equilibrium was tested
by a goodness-of-fit χ2 test to compare the observed
genotype frequencies to expected frequencies among
the control subjects. Associations between the genotypes
and dyslipidemia, CHD risk were estimated by computing
the odds ratios (OR) and 95 % confidence intervals (CIs)
from logistic regression analyses with adjustment for
age, sex, smoking status and body mass index (BMI).
The Chi-square-based Q test was used to test the
heterogeneity of associations between subgroups. The
effects of selected loci on plasma TC, TG and HDL-C
concentrations were evaluated using the multiple linear
regression method with adjustment for age, sex, smoking
status and BMI. The significance level was set at P < 0.05
and P values were given for two-sided tests. All statis-
tical analyses were performed using R software (Version
3.0.2, 2013-09-25; R Foundation for Statistical Comput-
ing, http://www.cran.r-project.org/). Data in this study
was available (Additional file 2).
Results
Characteristics of the subjects
The characteristics of the subjects are shown in Table 1.
There were no statistically significant differences between
the cases with dyslipidemia and the controls in terms of
age, sex, and smoking status. BMI (P < 0.0001), TC
(P < 0.0001) and TG (P < 0.0001) were significantly higher
in cases with dyslipidemia compared with the controls.
Mean HDL-C concentration in cases with dyslipidemia
(0.81 ± 0.18 mmol/L) was significantly lower than that in
controls (1.81 ± 0.31 mmol/L). Additionally, the mean age
of the CHD cases (67.61 ± 11.13 years) were significantly
higher than that of controls (49.48 ± 12.46 years). The pro-
portion of male in the CHD cases (57.96 %) was higher as
compared with those in controls (46.45 %) (P = 0.0001),
whereas similar distributions of smokers were observed be-
tween groups (P = 0.051). Besides, TC (P < 0.0001) and TG
(P < 0.0001) were significantly higher in the CHD cases than
that in controls. HDL-C (P< 0.0001) concentration was sig-
nificantly lower in the CHD cases compared with the controls.
Association analyses for dyslipidemia
The association results of 17 SNPs in codominant and addi-
tive models were described in Table 2. The SNP rs4499061
deviated from Hardy-Weinberg equilibrium among con-
trols (P < 0.05) and was excluded from subsequent analyses.
After adjustment of age, sex, smoking status and BMI, five
polymorphisms (KCTD10 rs1477117, KCTD10 rs11066782,
KCTD10 rs11613718, KCTD10 rs11615336 and MMAB
rs12817689) showed significant associations with dys-
lipidemia risk in the codominant model (minor homo-
zygote vs. major homozygote) and MMAB rs11067233
was significantly associated with dyslipidemia risk in
the additive model.
Association analyses for plasma lipid concentrations
We examined the effect of these six loci on plasma TC,
TG, or HDL-C concentrations, respectively, using a linear
Table 1 Characteristics of the subjects




(N = 465) (N = 399) (N = 697)
Age (years) 49.48 ± 12.46 48.97 ± 12.68 67.61 ± 11.13
BMI (kg/m2) 21.98 ± 3.01 25.34 ± 3.23
Sex
Male 216 (46.45) 193 (48.37) 404 (57.96)
Female 249 (53.55) 206 (51.63) 293 (42.04)
Smoking
Ever 148 (31.83) 131 (33.68) 185 (26.54)
Never 317 (68.17) 258 (66.32) 512 (73.46)
TC (mmol/L) 3.94 ± 0.60 4.37 ± 0.92 4.48 ± 2.05
TG (mmol/L) 0.75 ± 0.22 3.16 ± 1.33 1.61 ± 1.48
HDL-C (mmol/L) 1.81 ± 0.31 0.81 ± 0.18 1.18 ± 0.31
Data were shown as mean ± standard deviation (SD) or n (%)
BMI body mass index, TC total cholesterol, TG triglycerides, HDL-C
high-density lipoprotein-cholesterol
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regression model with adjustment for age, sex, smoking
status and BMI (Table 3). We found significant associa-
tions between rs11066782, rs11613718, rs11615336 and
rs12817689 and TC (codominant model: P = 0.035,
0.025, 0.005 and 0.038, respectively), between rs1477117,
rs11066782 and rs11615336 and TG (recessive model: P =
0.028, 0.015 and 0.031, respectively), between rs1477117,
rs11066782, rs11613718 and rs11615336 and HDL-C (re-
cessive model: P = 0.024, 0.007, 0.031 and 0.025, respect-
ively), between rs11067233 and HDL-C (dominant model:
P = 0.047). Additionally, the minor alleles of these associ-
ated SNPs were consistently associated with lower TC or
TG levels and higher HDL-C levels.
Association analyses for CHD
To further evaluate the associations of the significant
polymorphisms and CHD risk, we genotyped these six
promising SNPs in another 697 CHD cases. As shown in
Table 4, after adjustment of age, sex and smoking status,
the minor alleles of rs11066782 in KCTD10, rs11613718
in KCTD10 and rs11067233 in MMAB were signifi-
cantly associated with a decreased risk of CHD (addi-
tive model: OR = 0.71, 95 % CI = 0.53–0.97, P = 0.029
for rs11066782; OR = 0.73, 95 % CI = 0.54–0.99, P = 0.044
for rs11613718 and OR = 0.57, 95 % CI = 0.40–0.80, P =
0.001 for rs11067233).
Combined analyses were conducted to evaluate the cu-
mulative effect of the three significant loci (Table 5). Intri-
guingly, we found a significant allele-dosage association
between the number of favorable alleles and CHD risk
(Ptrend < 0.001). Compared with individuals carrying no fa-
vorable allele, those who carried “1–2” and “3–4” favorable
alleles had lower risk of CHD with adjusted ORs of 0.71
(0.50–0.99) and 0.33 (0.18–0.58), respectively. Individuals
carrying “3–4” favorable alleles had a 62 % (OR = 0.38,
95 % CI = 0.21–0.66) decreased risk of CHD compared
with those carrying “0–2” favorable alleles.
We also performed stratification analyses for the effect
of rs11066782, rs11613718 and rs11067233 based on age,
sex and smoking status (Additional file 3: Table S1). In
≥48 years group, rs11066782, rs11613718 and rs11067233
were significantly associated with a decreased risk of CHD
after adjustment for the other covariates (OR = 0.70, 95 %
CI = 0.50–0.97; OR = 0.71, 95 % CI = 0.51–0.99 and OR =
0.55, 95 % CI = 0.39–0.79, respectively). Sex stratification
analysis indicated that rs11613718 had statistically associ-
ated with CHD in male (OR = 0.61, 95 % CI = 0.38–0.98)
while rs11067233 had statistically associated with CHD in
Table 2 Summary results of associations between 17 potentially functional SNPs in three genes (KCTD10, MVK and MMAB) and risk
of dyslipidemia
Gene SNP Allelea Casesb Controlsb MAF HWEc Codominant modeld Additive modeld
(N = 399) (N = 465) (Cases/controls) P het P hom P add
KCTD10 rs1477117 G/A 279/115/1 326/123/10 0.148/0.156 0.686 0.349 0.025 0.791
rs11066782 C/T 283/113/1 311/135/11 0.145/0.172 0.414 0.929 0.014 0.174
rs11613718 C/T 272/120/1 308/139/9 0.155/0.172 0.138 0.762 0.038 0.521
rs11615336 C/A 282/101/1 317/120/10 0.134/0.157 0.730 0.931 0.024 0.288
rs7295954 C/T 322/60/1 381/69/0 0.081/0.077 0.078 0.399 – 0.323
rs1045582 G/T 284/104/2 321/124/6 0.138/0.151 0.118 0.888 0.112 0.459
MVK rs3759387 G/T 297/97/3 330/126/7 0.130/0.151 0.194 0.990 0.303 0.687
rs2287218 C/T 279/112/4 324/122/10 0.152/0.156 0.707 0.494 0.095 0.878
MMAB rs12817689 A/G 284/105/3 319/113/10 0.142/0.150 0.998 0.614 0.047 0.635
rs2241201 C/G 238/138/11 288/148/21 0.207/0.208 0.722 0.358 0.268 0.928
rs877710 C/G 194/177/26 219/201/40 0.288/0.305 0.522 0.656 0.330 0.714
rs11067233 C/G 315/74/2 329/118/8 0.100/0.147 0.486 0.072 0.145 0.026
rs9593 A/T 187/162/26 212/196/39 0.285/0.306 0.506 0.958 0.333 0.539
rs11067227 C/T 316/67/2 333/104/7 0.092/0.133 0.729 0.116 0.295 0.065
rs7134594 C/T 187/178/26 213/196/40 0.294/0.307 0.286 0.786 0.364 0.665
rs11831226 A/C 320/58/2 391/71/0 0.082/0.077 0.074 0.491 – 0.342
rs8228 A/G 322/63/0 380/69/0 0.082/0.077 0.078 0.349 – 0.349
MAF minor allele frequency
aMajor/minor allele
bMajor homozygote/heterozygote/rare homozygote
cHardy-Weinberg equilibrium test among controls
dLogistic regression with adjustment for sex, age, smoking and BMI were used to test associations in codominant (P het: heterozygote vs. major homozygote;
P hom: minor homozygote vs. major homozygote) and additive (P add: minor homozygote vs. heterozygote vs. major homozygote) models
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Table 3 Associations between selected single nucleotide polymorphisms and plasma lipid concentrations
Polymorphisms TC (mmol/L) Pa TG (mmol/L) Pa HDL-C (mmol/L) Pa
rs1477117 (G > A)
GG (n = 605) 4.17 ± 0.80 0.143 1.86 ± 1.49 0.848 1.34 ± 0.55 0.456
GA (n = 238) 4.11 ± 0.80 1.91 ± 1.58 1.35 ± 0.59
AA (n = 11) 3.68 ± 0.63 0.94 ± 0.50 1.68 ± 0.50
GG (n = 605) 4.17 ± 0.80 0.255 1.86 ± 1.49 0.733 1.34 ± 0.55 0.812
GA + AA (n = 249) 4.09 ± 0.80 1.87 ± 1.56 1.36 ± 0.59
GG + GA (n = 843) 4.15 ± 0.80 0.081 1.88 ± 1.52 0.028 1.34 ± 0.56 0.024
AA (n = 11) 3.68 ± 0.63 0.94 ± 0.50 1.68 ± 0.50
rs11066782 (C > T)
CC (n = 594) 4.19 ± 0.80 0.035 1.90 ± 1.50 0.319 1.33 ± 0.55 0.065
CT (n = 248) 4.07 ± 0.79 1.85 ± 1.58 1.38 ± 0.60
TT (n = 12) 3.82 ± 0.77 0.93 ± 0.48 1.71 ± 0.49
CC (n = 594) 4.19 ± 0.80 0.052 1.90 ± 1.50 0.653 1.33 ± 0.55 0.197
CT + TT (n = 260) 4.06 ± 0.79 1.80 ± 1.56 1.39 ± 0.59
CC + CT (n = 842) 4.15 ± 0.80 0.202 1.89 ± 1.52 0.015 1.34 ± 0.56 0.007
TT (n = 12) 3.82 ± 0.77 0.93 ± 0.48 1.71 ± 0.49
rs11613718 (C>T)
CC (n = 580) 4.18 ± 0.79 0.025 1.88 ± 1.50 0.599 1.33 ± 0.55 0.243
CT (n = 259) 4.07 ± 0.78 1.86 ± 1.56 1.37 ± 0.59
TT (n = 10) 3.71 ± 0.66 0.96 ± 0.52 1.70 ± 0.53
CC (n = 580) 4.18 ± 0.79 0.042 1.88 ± 1.50 0.914 1.33 ± 0.55 0.461
CT + TT (n = 269) 4.05 ± 0.78 1.83 ± 1.55 1.38 ± 0.59
CC + CT (n = 839) 4.15 ± 0.79 0.131 1.88 ± 1.52 0.053 1.34 ± 0.56 0.031
TT (n = 10) 3.71 ± 0.66 0.96 ± 0.52 1.70 ± 0.53
rs11615336 (C > A)
CC (n = 599) 4.19 ± 0.80 0.005 1.90 ± 1.51 0.191 1.34 ± 0.55 0.275
CA (n = 221) 4.03 ± 0.75 1.80 ± 1.53 1.36 ± 0.60
AA (n = 11) 3.68 ± 0.63 0.94 ± 0.50 1.68 ± 0.50
CC (n = 599) 4.19 ± 0.80 0.009 1.90 ± 1.51 0.392 1.34 ± 0.55 0.546
CA + AA (n = 232) 4.02 ± 0.75 1.76 ± 1.51 1.38 ± 0.60
CC + CA (n = 820) 4.15 ± 0.79 0.082 1.87 ± 1.51 0.031 1.34 ± 0.56 0.025
AA (n = 11) 3.68 ± 0.63 0.94 ± 0.50 1.68 ± 0.50
rs12817689 (A > G)
AA (n = 603) 4.18 ± 0.80 0.038 1.89 ± 1.50 0.733 1.34 ± 0.55 0.423
AG (n = 218) 4.06 ± 0.78 1.90 ± 1.58 1.35 ± 0.60
GG (n = 13) 3.88 ± 0.67 1.34 ± 1.20 1.54 ± 0.57
AA (n = 603) 4.18 ± 0.80 0.051 1.89 ± 1.50 0.995 1.34 ± 0.55 0.669
AG + GG (n = 231) 4.05 ± 0.77 1.87 ± 1.56 1.36 ± 0.60
AA + AG (n = 821) 4.14 ± 0.79 0.278 1.89 ± 1.52 0.172 1.34 ± 0.56 0.099
GG (n = 13) 3.88 ± 0.67 1.34 ± 1.20 1.54 ± 0.57
rs11067233 (C > G)
CC (n = 644) 4.15 ± 0.80 0.392 1.94 ± 1.54 0.123 1.32 ± 0.56 0.049
CG (n = 192) 4.17 ± 0.82 1.68 ± 1.46 1.44 ± 0.55
GG (n = 10) 4.10 ± 0.63 1.38 ± 1.12 1.51 ± 0.42
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female (OR = 0.35, 95 % CI = 0.20–0.62) after adjustment
for covariates respectively. Besides, rs11067233 was signifi-
cantly associated with a decreased risk of CHD in never-
smokers after adjustment for relevant covariates (OR =
0.37, 95 % CI = 0.23–0.59).
Discussion
In this study, we investigated the relationship of 17 SNPs
located in three genes (MVK, MMAB and KCTD10) with
HDL-C concentrations and CHD risk in a Chinese popu-
lation. We found that rs11067233 in MMAB, rs11066782
and rs11613718 in KCTD10 were associated with HDL-C
concentrations and with CHD risk.
The KCTD10 gene, located on chromosome 12q24, is
a member of the polymerase delta-interacting protein 1
gene family [20]. Reports showed that KCTD10 was highly
expressed in human heart, skeletal muscle, and placenta,
and play a vital role in DNA synthesis by interacting with
proliferating cell nuclear antigen and polymerase δ [21].
In A549 lung adenocarcinoma cells, down-regulation of
KCTD10 could inhibit cell proliferation [22]. Transcrip-
tion factors SP1 and AP-2α could bind to the promoter
region of human KCTD10, and regulate its expression
[23]. A recent study revealed KCTD10 as a novel prog-
nostic biomarker in gastrointestinal stromal tumor [24].
According to Chen et al., Murine Kctd10 has been im-
plicated in a metabolic network perturbed by loci con-
tributing to the susceptibility of obesity, diabetes, and
atherosclerosis [18]. And by extension, the involvement
of human KCTD10 in this metabolic network supports
its association with HDL-C concentrations and CHD
development. In the present study, we found, for the first
time, that the minor alleles of rs11066782 and rs11613718
in KCTD10 were associated with higher HDL-C concen-
trations and lower CHD risk in a Chinese population.
Since high levels of HDL-C could reduce the risk of is-
chaemic heart disease [8, 25], it is reasonable that the
variant genotypes of the two polymorphisms may affect
CHD susceptibility by increasing HDL-C concentrations.
Located at intron 1 of KCTD10 gene, the two SNPs are in
high linkage disequilibrium with each other (r2 = 0.92),
and both of them may affect gene expression by altering
transcription factor binding sites (TFBS) of KCTD10 based
on SNPinfo Web Server (http://snpinfo.niehs.nih.gov/).
Analysis of Encyclopedia of DNA Elements data as im-
plemented in online tool, RegulomeDB (http://regulo-
medb.org/), indicated that the two polymorphisms may
influence the histone modifications and the expression
of KCTD10, which may serve as regulatory variants in
the development of coronary heart disease. Moreover,
data from GTEx (http://www.gtexportal.org/home/) re-
vealed that variant genotypes of the two potential SNPs
were significantly associated with higher expression levels
of KCTD10 in liver tissues in all HapMap subjects (P =
0.041 for rs11066782 and P = 0.038 for rs11613718, re-
spectively; Additional file 4: Figure S2a, b). Besides, strati-
fied analyses subsequently demonstrated that the protective
effects of the variant genotypes were greater in those aged
≥48 years for rs11066782 and rs11613718, and greater
in men for rs11613718 compared with other individ-
uals. Since the prevalence of CHD increases with ad-
vancing age [26, 27] and is greater in men than women
Table 3 Associations between selected single nucleotide polymorphisms and plasma lipid concentrations (Continued)
CC (n = 644) 4.15 ± 0.80 0.347 1.94 ± 1.54 0.137 1.32 ± 0.56 0.047
CG + GG (n = 202) 4.17 ± 0.81 1.66 ± 1.44 1.44 ± 0.55
CC + CG (n = 836) 4.15 ± 0.80 0.952 1.88 ± 1.52 0.482 1.35 ± 0.56 0.591
GG (n = 10) 4.10 ± 0.63 1.38 ± 1.12 1.51 ± 0.42
TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein-cholesterol
aMultiple linear regression with adjustment for sex, age, smoking and BMI
Table 4 Associations between selected single nucleotide polymorphisms and risk of coronary heart disease
Gene SNP Casesa Controlsa MAF Heterozygote vs. major
homozygote
Minor homozygote vs. major
homozygote
Additive model
(N = 697) (N = 465) (Cases/controls) OR (95 % CI)b Pb OR (95 % CI)b Pb OR (95 % CI)b Pb
KCTD10 rs1477117 521/156/16 326/123/10 0.136/0.156 0.70 (0.49–1.00) 0.048 1.13 (0.39–3.33) 0.820 0.79 (0.58–1.08) 0.135
rs11066782 517/160/15 311/135/11 0.137/0.172 0.62 (0.43–0.88) 0.007 1.02 (0.35–2.94) 0.975 0.71 (0.53–0.97) 0.029
rs11613718 494/160/15 308/139/9 0.142/0.172 0.63 (0.44–0.90) 0.010 1.12 (0.37–3.35) 0.840 0.73 (0.54–0.99) 0.044
rs11615336 502/166/16 317/120/10 0.145/0.157 0.74 (0.52–1.06) 0.104 1.12 (0.38–3.30) 0.835 0.83 (0.61–1.12) 0.223
MMAB rs12817689 519/158/15 319/113/10 0.136/0.150 0.78 (0.54–1.12) 0.173 1.10 (0.38–3.21) 0.865 0.85 (0.62–1.16) 0.311
rs11067233 562/122/7 329/118/8 0.098/0.147 0.50 (0.34–0.73) <0.001 0.73 (0.20–2.67) 0.631 0.57 (0.40–0.80) 0.001
MAF minor allele frequency, OR odds ratio, CI confidence interval
aMajor homozygote/heterozygote/rare homozygote
bLogistic regression with adjustment for sex, age and smoking
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[28], it is reasonable that such genetic effects are more
evident among the older people and men. Nevertheless,
larger sample size and multi-ethnic population studies
are warranted to support our findings.
In humans, MVK and MMAB are arranged in a head-
to-head orientation on chromosome 12. Through a shared
common promoter, MVK and MMAB are both regulated
by sterol-responsive element-binding protein 2 (SREBP2),
which is a transcription factor that controls cholesterol
homeostasis [17]. Furthermore, it is also reported that
these two neighboring genes participate in metabolic path-
ways associated with HDL metabolism. MVK encodes for
mevalonate kinase, which catalyzes an early step in the
biosynthesis of cholesterol [17]. Homozygosity for milder
mutations in MVK could cause hyperimmunoglobuline-
mia D syndrome (HIDS), which is characterized by fever
and increased levels of immunoglobulin D and A [29, 30].
In keeping with GWAS findings [13, 14], patients with
HIDS have low HDL-C concentrations. However, in our
study, neither rs3759387 in MVK nor rs2287218 in MVK
showed a consistent result with the previous studies. The
effects of SNPs on dyslipidemia might differ according to
different ethnic background, as the rs3759387 T allele
and rs2287218 T allele were found to be more enriched
in the Caucasians than in Asians; Additionally, these dis-
crepancies may be due to differences in lifestyle across
populations. Functional characterizations are warranted to
determine the causal variants related to plasma lipid con-
centrations in Asian populations. MMAB encodes the
cob(I)alamin adenosyltransferase, an enzyme involved in
the formation of adenosylcobalamin, necessary for deg-
radation of cholesterol [17]. In humans, deficiency of
cob(I)alamin adenosyltransferase results in methylmalo-
nic aciduria [31], and a negative correlation between
urinary methylmalonic acid and red blood cell membrane
cholesterol concentrations was also found in patients with
schizophrenia [32]. According to Junyent et al., homozy-
gotes for major alleles at SNPs MMAB 3U3527G > C
displayed lower HDL-C concentrations than carriers of
the minor alleles when they consumed diets rich in carbo-
hydrates [33]. Besides, Marie et al. observed significant
allelic expression imbalance of 22 % in MMAB (tran-
scribed SNP rs11067231) and the allele associated with
lower HDL-C level displayed greater MMAB transcript
level. This result indicated that MMAB was a likely sus-
ceptibility gene influencing HDL-C levels [34]. In addition,
MMAB can affect TG levels through adenosylcobala-
min, methylmalonyl-CoA mutase [35] and homocysteine
[36, 37] based on several related function researches. In this
study, we found that the variant genotypes of rs11067233
were associated with higher HDL-C concentrations and
lower CHD risk. According to SNPinfo Web Server,
rs11067233 may affectMMAB gene expression by altering
microRNA binding at the 3′UTR of MMAB. Meanwhile,
rs11067233 C >G could result in the loss of hsa-miR-603
binding to MMAB with energy change of 20.90, as pre-
dicted by miRNASNP v2.0 (http://bioinfo.life.hust.edu.cn/
miRNASNP2/), which is a online database that predicts
the effect (loss or gain of function) of miRNA-related
SNPs based on miRNA expression data, GWAS informa-
tion and experimental validation results. Additionally, data
from GTEx project suggested that the variant genotypes
of rs11067233 showed relatively lower expression levels
of MMAB in liver tissues compared with homozygotes,
although the difference did not reach the statistical sig-
nificance level (P = 0.078; Additional file 4: Figure S2c).
Moreover, Fogarty et al. also found that the C allele of
rs11067233 demonstrated 15 % higher MMAB expres-
sion than the G allele in human hepatocytes [34]. Taken
together, it is plausible that rs11067233 is associated
with MMAB gene expression, which therefore could alter
serum lipid concentrations, and accordingly modify the
risk of coronary artery disease. Notably, we found that
rs11067233 genotypes were significantly associated with
lower risk of CHD among never-smokers and females. As
cigarette use is a well-established risk factor for CHD
[38, 39] and most of the never-smokers in China are fe-
males, the protective effect of rs11067233 may be diluted
by environmental risk factors if they do not have a joint ef-
fect. Anyhow, further investigations in relation to bio-
logical mechanisms may lead to important insights for
these findings.
Several limitations of our study should be considered.
Though we observed significantly main effects of three
polymorphisms on CHD risk, only rs11067233 remained
significant after Bonferroni correction for multiple com-
parisons (P < 0.010, Bonferroni-adjusted), suggesting that
larger well-designed studies are warranted to confirm
the associations identified in our study. Secondly, the
sample size was moderate with limited power to detect
significant associations. Thirdly, inherent selection bias
could not be completely excluded due to the unbalanced
Table 5 Combined analysis of the cumulative effect of
rs11066782, rs11613718 and rs11067233 on coronary heart
disease risk
Combined genotypesa Cases Controls OR (95 % CI)b Pb
0 383 222 1.00
1–2 244 166 0.71 (0.50–0.99) 0.045
3–4 33 55 0.33 (0.18–0.58) <0.001
P for trend <0.001
0–2 627 388 1.00
3–4 33 55 0.38 (0.21–0.66) <0.001
OR odds ratio, CI confidence interval
aThe combined genotypes were according to favorable alleles carried
(rs11066782-T, rs11613718-T and rs11067233-G were considered as
favorable alleles)
bLogistic regression with adjustment for sex, age and smoking
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matching in age and sex. Finally, some other confound-
ing factors may potentially mediate the effect of selected
polymorphisms on dyslipidemia and CHD risk such as
alcohol consumption, physical activity, family history of
cardiovascular diseases and so on. However, we applied
a rigorous epidemiological design and laboratory tests
and statistically adjusted for several known risk factors
to minimize potential bias.
Conclusions
In conclusion, we found that rs11067233 in MMAB,
rs11066782 and rs11613718 in KCTD10 were associated
with higher HDL-C concentrations and lower CHD risk
in a Chinese population. Further studies incorporating
diverse populations and functional assays are required to
validate and extend these findings.
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